OTCMKTS:SGIOY Shionogi & Co., Ltd. Unsponsored ADR Q2 2027 Earnings Results & Report $9.44 +0.01 (+0.11%) As of 03:59 PM Eastern Shionogi & Co., Ltd. Unsponsored ADR missed analyst earnings expectations in its Q2 2027 results, released October 29, 2026. The company reported EPS of $0.08 versus the $0.13 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2027Report DateOctober 29, 2026TimeAfter Market Closes Shionogi & Co., Ltd. Unsponsored ADR EPS ResultsActual EPS$0.08Consensus EPS $0.13Beat/MissMissed by -$0.05One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersShionogi & Co., Ltd. Unsponsored ADR Revenue ResultsActual RevenueN/AExpected Revenue$1.11 billionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Shionogi & Co., Ltd. Unsponsored ADR Q2 2027 Earnings FAQ Did Shionogi & Co., Ltd. Unsponsored ADR beat earnings estimates for Q2 2027? Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) reported earnings of $0.08 per share for Q2 2027, missing the consensus estimate of $0.13. The report was announced on Thursday, October 29, 2026. Shionogi & Co., Ltd. Unsponsored ADR Earnings HeadlinesShionogi & Co., Ltd. unsponsored ADR (SGIOY) Q2 earnings lag estimatesOctober 29 at 12:38 PM | msn.comShionogi & Co., Ltd. Unsponsored ADR (SGIOY) Projected to Post Earnings on MondayOctober 19, 2026 | americanbankingnews.comElon Musk's Intel Deal Already Jumped 177 Percent This YearElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the analyst who flagged Nvidia in 2016 before its 37,800% run, says Musk may announce a new AI partnership by October 30.October 29 at 1:00 AM | Brownstone Research (Ad)Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Up 6.2% After Analyst UpgradeOctober 18, 2026 | americanbankingnews.comShionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should KnowOctober 14, 2026 | msn.comAll You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to BuyFebruary 4, 2026 | msn.comSee More Shionogi & Co., Ltd. Unsponsored ADR Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd. Unsponsored ADR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. Unsponsored ADR and other key companies, straight to your email. Email Address About Shionogi & Co., Ltd. Unsponsored ADRShionogi & Co., Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies. Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas. Shionogi has also participated in the development and commercialization of HIV treatments through partnerships with international pharmaceutical companies. Shionogi serves patients primarily in Japan and maintains international commercial and research activities through subsidiaries and partnerships in North America, Europe and other markets. The company is led by Isao Teshirogi, who serves as president and chief executive officer.View Shionogi & Co., Ltd. Unsponsored ADR ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
